Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
US biotech Insmed positions Japan as the “cornerstone” of its entire Asia-Pacific strategy, looking to at least double the workforce of its local arm in the next couple of years to underpin the company’s expected growth, Chair and CEO Will…
To read the full story
Related Article
- Insmed Japan to Double Sales Force with Brensocatib Launch on the Horizon
November 28, 2025
- Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
- Insmed Revs Up for Product Expansion in Japan, Arikayce Frontline Filing Set for 2026 with More to Follow
February 28, 2024
- Insmed Plots Growth in Japan Biz with Arikayce and More Drugs to Follow
February 8, 2022
BUSINESS
- Gilead Files CAR-T Therapy Tecartus in Japan for MCL, B-ALL
August 21, 2026
- Tiger, Gaudi Develop Compact Cell Transport Container
August 21, 2026
- Sawai’s Solo Tenelia Copy Raises Patent Questions Ahead of December Listing
August 21, 2026
- DT-Axis Charts Path to 2nd-Stage DTx Approval with Depression App
August 21, 2026
- Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…